Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Claudia M. Trujillo-Vargas is active.

Publication


Featured researches published by Claudia M. Trujillo-Vargas.


Immunopharmacology and Immunotoxicology | 2011

New promising Euphorbiaceae extracts with activity in human lymphocytes from primary cell cultures.

Doris S. Llanes-Coronel; Laura Y. Gámez‐Díaz; Leidy P. Suarez-Quintero; Lady J. Páez; Fernando Torres; Fernando Echeverri; Pablo Javier Patiño; Claudia M. Trujillo-Vargas

Context: Euphorbiaceae plants exhibit anti-inflammatory and immunomodulatory properties. Methods: We evaluated the activity of 14 extracts from seven Euphorbiaceae plants on primary immune cell cultures from healthy individuals. Peripheral blood mononuclear cells (PBMC) were exposed to the extracts w/o phytohaemagglutinin A or cycloheximide as agents that induce proliferation or apoptosis in PBMC, respectively. Results: We found that five up to 14 Euphorbiaceae’s extracts had the ability to modulate at least one of the immune parameters evaluated in this study. However, only the latex extracts of Euphorbia cotinifolia and Euphorbia tirucalli strongly induced both proliferation and apoptosis in PBMC. These extracts were further subfractioned by silica gel column chromatography. Two subfractions with enhanced activity in comparison to the crude extracts were obtained. Although these subfractions induced proliferation on both CD3+ and CD3− cells, the most prominent effects were observed in the former subpopulation. Interestingly, the subfraction from E. tirucalli induced lymphocyte proliferation without the need of accessory cells; this ability was not inhibited by the carbohydrates d-galactose and α-Methyl-d-Mannopyranoside. Conclusions: Altogether, these results reveal the presence of novel candidates within the Euphorbia plants to induce proliferation and apoptosis in human lymphocytes, mainly in CD3+ T cells.


Biomedica | 2011

An immunoenzymatic test for IgG antibody levels against 10 serotypes of Streptococcus pneumoniae

Lucía Carolina Leal-Esteban; Jessica Lineth Rojas; Andrea Lizeth Jaimes; Juan David Montoya; Nilton Edu Montoya; Lily Leiva; Claudia M. Trujillo-Vargas

INTRODUCTION Streptococcus pneumoniae is a major cause of morbi-mortality in early childhood and elderly. However, a test to measure the antibody responses after specific vaccination is not available in Colombia. OBJECTIVE An immunoenzymatic test was standardized for the measurement of serum IgG levels against 10 serotypes of S. pneumoniae in response to the specific vaccination. MATERIAL AND METHODS Capsular polysaccharides 1, 3, 4, 5, 6B, 9V, 14, 18, 19F, 23F of S. pneumoniae were used as antigens in a solid-phase ELISA. These responses were characterized in a randomized selected healthy individuals from a Colombian population. RESULTS The reference and control sera showed great reactivity against all the polysaccharides evaluated, especially against polysaccharide 14 and 19F. The lowest reactivity in these two sera was observed against polysaccharide 3 and 4. Among the children evaluated, polysaccharide 5/19F showed the highes pre-vaccination reactivity, and polysaccharide 14/19F showed the highest post-vaccination reactivity. Among the adults, polysaccharides 14 and 19F showed the greatest reactivity pre- and post-vaccination. For all the polysaccharides (excepting polysaccharide 5), an inverse association among high polysaccharide-specific pre-vaccination- and the increase of post-vaccination-IgG levels was observed. CONCLUSION This ELISA test reliably quantifies the serum levels of specific IgG against 10 serotypes of S. pneumoniae. According to the responses by healthy individuals, the current study validates parameters used internationally as an adequate the response to the 23-valent pneumococcal vaccine.


Frontiers in Immunology | 2017

Human CD56dimCD16dim Cells As an Individualized Natural Killer Cell Subset

Mathieu Amand; Gilles Iserentant; Aurélie Poli; Marwan Sleiman; Virginie Fievez; Isaura Pilar Sánchez; Nicolas Sauvageot; Tatiana Michel; Nasséra Aouali; Bassam Janji; Claudia M. Trujillo-Vargas; Carole Seguin-Devaux; Jacques Zimmer

Human natural killer (NK) cells can be subdivided in several subpopulations on the basis of the relative expression of the adhesion molecule CD56 and the activating receptor CD16. Whereas blood CD56brightCD16dim/− NK cells are classically viewed as immature precursors and cytokine producers, the larger CD56dimCD16bright subset is considered as the most cytotoxic one. In peripheral blood of healthy donors, we noticed the existence of a population of CD56dimCD16dim NK cells that was frequently higher in number than the CD56bright subsets and even expanded in occasional control donors but also in transporter associated with antigen processing-deficient patients, two familial hemophagocytic lymphohistiocytosis type II patients, and several common variable immunodeficiency patients. This population was detected but globally reduced in a longitudinal cohort of 18 HIV-1-infected individuals. Phenotypically, the new subset contained a high percentage of relatively immature cells, as reflected by a significantly stronger representation of NKG2A+ and CD57− cells compared to their CD56dimCD16bright counterparts. The phenotype of the CD56dimCD16dim population was differentially affected by HIV-1 infection as compared to the other NK cell subsets and only partly restored to normal by antiretroviral therapy. From the functional point of view, sorted CD56dimCD16dim cells degranulated more than CD56dimCD16bright cells but less than CD56dimCD16− NK cells. The population was also identified in various organs of immunodeficient mice with a human immune system (“humanized” mice) reconstituted from human cord blood stem cells. In conclusion, the CD56dimCD16dim NK cell subpopulation displays distinct phenotypic and functional features. It remains to be clarified if these cells are the immediate precursors of the CD56dimCD16bright subset or placed somewhere else in the NK cell differentiation and maturation pathway.


Scandinavian Journal of Immunology | 2017

Skewed invariant natural killer T (iNKT) cells, impaired iNKT:B-cell help and decreased SAP expression in blood lymphocytes from patients with common variable immunodeficiency

Lucía Victoria Erazo-Borrás; Jesús A. Álvarez-Álvarez; Camilo Andrés Pérez-Romero; Julio C. Orrego-Arango; José L. Franco-Restrepo; Claudia M. Trujillo-Vargas

Common variable immunodeficiency (CVID) is a syndrome with predominantly defective B cell function. However, abnormalities in the number and function of other lymphocyte subpopulations in peripheral blood (PB) have been described in most patients. We have analysed the distribution of iNKT cell subpopulations in the PB of CVID patients and the ability of these cells to provide in vitro cognate B cell help. The total of iNKT cells was reduced in the PB of CVID patients, especially CD4+, CD4‐/CD8‐ and CCR5+/CXCR3+. These findings were associated with an enrichment of memory‐like and a tendency towards a reduction in TNF‐α‐expressing effector iNKT cells in the peripheral blood mononuclear cells (PBMC) of CVID patients. Moreover, an accumulation of follicular helper iNKT cells in the PB of CVID patients was demonstrated. CVID αGalCer‐pulsed iNKT cells are not able to induce autologous B cell proliferation although they do induce proliferation to healthy donor B cells. Interestingly, autologous and heterologous co‐cultures did not differ in the amount of immunoglobulin secreted by B cells in vitro. Finally, reduced intracellular SAP expression in iNKT cells and other lymphocytes in the blood from CVID patients was observed. These results provide further insights into the immunological mechanisms underlying the iNKT cell defects and the potential targets to improve B cell help in CVID.


Journal of Clinical Immunology | 2015

A Novel Pathogenic Variant in PRF1 Associated with Hemophagocytic Lymphohistiocytosis

Camilo Andrés Pérez Romero; Isaura Pilar Sánchez; Sebastian Gutierrez-Hincapié; Jesús A. Álvarez-Álvarez; Jaime Andrés Pereañez; Rodrigo Ochoa; Carlos Enrique Muskus-López; Ruth G. Eraso; Carolina Echeverry; Catalina Arango; José Luis Franco Restrepo; Claudia M. Trujillo-Vargas

Familial Hemophagocytic Lymphohistiocytosis type 2 (FHL2) results from mutations in PRF1. We described two unrelated individuals who presented with FHL, in whom severely impaired NK cytotoxicity and decrease perforin expression was observed. DNA sequencing of PRF1 demonstrated that both were not only heterozygous for the p.54R > C/91A > V haplotype but also presented with the novel variant p.47G > V at the perforin protein. Perforin mRNA was found to be increased in a individual with that genotype. A carrier of the novel variant also demonstrated altered perforin mRNA and protein expression. Phylogenetic analysis and multiple alignments with perforin orthologous demonstrated a high level of conservation at Gly47. PolyPhen-2 and PROVEAN predicted p.47G > V to be “probably damaging” and “deleterious”, respectively. A thermodynamic analysis showed that this variant was highly stabilizing, decreasing the protein internal energy. The ab initio perforin molecular modeling indicated that Gly47 is buried inside the hydrophobic core of the MACPF domain, which is crucial for the lytic pore formation and protein oligomerization. After the in silico induction of the p.47G > V mutation, Val47 increased the interactions with the surrounding amino acids due to its size and physical properties, avoiding a proper conformational change of the domain. To our knowledge, this is the first description supporting that p.47G > V is a pathogenic variant that in conjunction with p.54R > C/91A > V might result in the clinical phenotype of FHL2.


Journal of Clinical Immunology | 2012

Analyses of the PRF1 Gene in Individuals with Hemophagocytic Lymphohystiocytosis Reveal the Common Haplotype R54C/A91V in Colombian Unrelated Families Associated with Late Onset Disease

Isaura Pilar Sánchez; Lucía Carolina Leal-Esteban; Jesús A. Álvarez-Álvarez; Camilo Andrés Pérez-Romero; Julio César Orrego; Malyive L. Serna; Yadira Coll; Yolanda Caicedo; Edwin Pardo-Díaz; Jacques Zimmer; Jack Bleesing; José Luis Franco; Claudia M. Trujillo-Vargas


Vaccine | 2016

Adverse events following immunization in patients with primary immunodeficiencies

Juan David Sarmiento; Fabio Villada; Julio César Orrego; José Luis Franco; Claudia M. Trujillo-Vargas


Infectio | 2016

Abordaje inmunológico del síndrome por deleción 22q11.2

Estefanía Vásquez-Echeverri; Federico Sierra; Claudia M. Trujillo-Vargas; Julio C. Orrego-Arango; Carlos Garcés-Samudio; Rafael Lince; José Luis Franco


Inmunología | 2014

Validación de la técnica de dihidrorodamina 123 para el diagnóstico de la enfermedad granulomatosa crónica en Colombia

Jessica Lineth Rojas-Restrepo; Jesús A. Álvarez-Álvarez; Juan David Montoya-Giraldo; Claudia M. Trujillo-Vargas


Inmunología | 2014

Linfocitos NKT invariantes: ontogenia, fenotipo y función

Lucía Victoria Erazo-Borrás; Jesús A. Álvarez-Álvarez; Claudia M. Trujillo-Vargas

Collaboration


Dive into the Claudia M. Trujillo-Vargas's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge